Drug Trial Radar · NCT02494778
A Study Evaluating if Pridopidine is Safe, Efficacious, and Tolerable in Patients With Huntington's Disease
Last checked: Nov 19, 2026Latest source record: Sep 17, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
248
Actual
Start
Sep 24, 2015
Primary completion
Jan 12, 2018
Study completion Jan 12, 2018
Sponsor
- Lead sponsor
- PrileniaIndustry
- Sponsor type
- Industry
- First posted
- Jul 10, 2015
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 21 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of the study is to collect and assess long term data on the safety, tolerability, and efficacy of pridopidine in patients with Huntington's disease (HD).
Conditions
- Huntington's Disease
Interventions
PridopidineDrug
45 mg BID
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants With Adverse EventsTime frame: 106 weeks
Locations
46 sites in 11 countries. Site status is shown where the registry gives one.
Teva Investigational Site 12204
Los Angeles, California
Teva Investigational Site 12201
Englewood, Colorado
Teva Investigational Site 12196
Washington D.C., District of Columbia
Teva Investigational Site 12206
Baltimore, Maryland
Teva Investigational Site 12200
Manhasset, New York
Teva Investigational Site 12203
New York, New York
Teva Investigational Site 12198
Rochester, New York
Teva Investigational Site 12211
Winston-Salem, North Carolina
Teva Investigational Site 12209
Pittsburgh, Pennsylvania
Teva Investigational Site 12208
Salt Lake City, Utah
Teva Investigational Site 12210
Richmond, Virginia
Teva Investigational Site 78055
Caulfield South, Australia
Teva Investigational Site 78058
West Perth, Australia
Teva Investigational Site 78057
Westmead, Australia
Teva Investigational Site 33021
Innsbruck, Austria
Teva Investigational Site 33027
Vienna, Austria
Teva Investigational Site 11036
Toronto, Ontario, Canada
Teva Investigational Site 35123
Angers, France
Teva Investigational Site 35122
Créteil, France
Teva Investigational Site 35125
Lille, France
Teva Investigational Site 35124
Marseille, France
Teva Investigational Site 35121
Salouël, France
Teva Investigational Site 35165
Toulouse, France
Teva Investigational Site 32408
Berlin, Germany
Teva Investigational Site 32410
Bochum, Germany
Teva Investigational Site 32409
Münster, Germany
Teva Investigational Site 32407
Ulm, Germany
Teva Investigational Site 30083
Florence, Italy
Teva Investigational Site 30080
Milan, Italy
Teva Investigational Site 30082
Naples, Italy
Teva Investigational Site 30081
San Giovanni Rotondo, Italy
Teva Investigational Site 38059
Leiden, Netherlands
Teva Investigational Site 53150
Gdansk, Poland
Teva Investigational Site 53149
Krakow, Poland
Teva Investigational Site 53148
Poznan, Poland
Teva Investigational Site 53151
Warsaw, Poland
Teva Investigational Site 50215
Kazan', Russia
Teva Investigational Site 50213
Moscow, Russia
Teva Investigational Site 50214
Nyznij Novgorod, Russia
Teva Investigational Site 34058
Birmingham, United Kingdom
Showing 40 of 46 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.